Intérêts de la daptomycine dans les infections ostéo-articulaires à Staphylococcus aureus

La vancomycine est l'antibiotique de référence dans les infections ostéo-articulaires à Staphylococcus aureus résistant à la méticilline. Le traitement de telles infections est long et coûteux, grevé d'effets indésirables et d un taux d'échec non négligeable. L'efficacité de la daptomycine, premier représentant de la classe des lipopeptides, a été évaluée in vitro et in vivo, seule ou en association à la rifampicine dans un modèle d'ostéo-arthrite aiguë à Staphylococcus aureus résistant à la méticilline chez le lapin. Cinq cas d infections ostéo-articulaires à staphylocoque traitées par daptomycine au CHU de Nantes ont été rapportés. In vitro, la daptomycine était rapidement bactéricide sur l ensemble des souches bactériennes et la rifampicine exerçait sur elle un effet antagoniste à 24 heures. Dans le modèle expérimental, après quatre jours de monothérapie par la daptomycine, la réduction de la charge bactérienne au foyer infectieux n'était pas différente de celle obtenue sous vancomycine. Par contre, associée à la rifampicine, la daptomycine exerçait une activité bactéricide significativement plus importante que celle obtenue par les deux monothérapies et par l'association vancomycine et rifampicine dans le liquide articulaire. Enfin, l'évolution des cinq sujets traités par daptomycine au CHU de Nantes était favorable. L'association daptomycine et rifampicine pourrait être une alternative au traitement conventionnel des infections ostéo-articulaires et doit être évaluée par des essais thérapeutiques.NANTES-BU Médecine pharmacie (441092101) / SudocSudocFranceF

Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012–2018

International audienceBackground: The arrival of highly effective, well tolerated direct-acting antiviral agents (DAA) led to a dramatic decrease in HCV prevalence. HIV-HCV coinfected patients are deemed a priority population for HCV elimination, while a rise of recently acquired HCV infections in MSM has been described. We describe the variations in HIV-HCV epidemiology in the French Dat'AIDS cohort.Methods: Retrospective analysis of a prospective HIV-infected cohort from 2012 to 2018. Determination of HCV prevalence, incidence, proportion of viremic patients, treatment uptake and mortality rate in the full cohort and by HIV risk factors.Results: From 2012 to 2018, 50861 HIV-infected patients with a known HCV status were followed-up. During the period, HCV prevalence decreased from 15.4% to 13.5%. HCV prevalence among new HIV cases increased from 1.9% to 3.5% in MSM but remained stable in other groups. Recently acquired HCV incidence increased from 0.36/100PY to 1.25/100PY in MSM. The proportion of viremic patients decreased from 67.0% to 8.9%. MSM became the first group of viremic patients in 2018 (37.9%). Recently acquired hepatitis represented 59.2% of viremic MSM in 2018. DAA treatment uptake increased from 11.4% to 61.5%. More treatments were initiated in MSM in 2018 (41.2%) than in IVDU (35.6%). In MSM, treatment at acute phase represented 30.0% of treatments in 2018.Conclusions: A major shift in HCV epidemiology was observed in HIV-infected patients in France from 2012 to 2018, leading to a unique situation in which the major group of HCV transmission in 2018 was MSM

Severe Symptomatic Primary Human Cytomegalovirus Infection despite Effective Innate and Adaptive Immune Responses

International audiencePrimary human cytomegalovirus (HCMV) infection usually goes unnoticed, causing mild or no symptoms in immunocompetent individuals. However, some rare severe clinical cases have been reported without investigation of host immune responses or viral virulence. In the present study, we investigate for the first time phenotypic and functional features, together with gene expression profiles in immunocompetent adults experiencing a severe primary HCMV infection. Twenty primary HCMV-infected patients (PHIP) were enrolled, as well as 26 HCMV-seronegative and 39 HCMV-seropositive healthy controls. PHIP had extensive lymphocytosis marked by massive expansion of natural killer (NK) and T cell compartments. Interestingly, PHIP mounted efficient innate and adaptive immune responses with a deep HCMV imprint, revealed mainly by the expansion of NKG2C+ NK cells, CD16+ Vδ2(-) γδ T cells, and conventional HCMV-specific CD8+ T cells. The main effector lymphocytes were activated and displayed an early immune phenotype that developed toward a more mature differentiated status. We suggest that both massive lymphocytosis and excessive lymphocyte activation could contribute to massive cytokine production, known to mediate tissue damage observed in PHIP. Taken together, these findings bring new insights into the comprehensive understanding of immune mechanisms involved during primary HCMV infection in immunocompetent individuals.IMPORTANCE HCMV-specific immune responses have been extensively documented in immunocompromised patients and during in utero acquisition. While it usually goes unnoticed, some rare severe clinical cases of primary HCMV infection have been reported in immunocompetent patients. However, host immune responses or HCMV virulence in these patients has not so far been investigated. In the present study, we show massive expansion of NK and T cell compartments during the symptomatic stage of acute HCMV infection. The patients mounted efficient innate and adaptive immune responses with a deep HCMV imprint. The massive lymphocytosis could be the result of nonadapted or uncontrolled immune responses limiting the effectiveness of the specific responses mounted. Both massive lymphocytosis and excessive lymphocyte activation could contribute to massive cytokine production, known to mediate tissue damage. Furthermore, we cannot exclude a delayed immune response caused by immune escape established by HCMV strains

A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project

International audienc

Utility of hyposmia and hypogeusia for the diagnosis of COVID-19

International audience[No abstract available

Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years

Immune response induced by COVID-19 vaccine booster against delta and omicron variants was assessed in 65 adults (65-84 years old) early aftesr a first booster dose. An increase in SARS-CoV-2 neutralizing antibodies was shown in individuals not previously infected without evidence of an age-related effect, with lower increase in those infected before a single dose of primary vaccination. Of note, humoral response was observed only starting from the 5th day after the boost